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Abstract: One of the major reasons for mortality throughout the world is cardiovascular diseases. 
Therefore, bio-markers of cardiovascular disease are of high importance to diagnose and manage pro-
cedure. Detecting biomarkers provided a promising procedure in developing bio-sensors. Fast, selec-
tive, portable, accurate, inexpensive, and sensitive biomarker sensing instruments will be necessary for 
detecting and predicting diseases. One of the cardiac biomarkers may be ordered as C-reactive proteins, 
lipoprotein-linked phospho-lipase, troponin I or T, myoglobin, interleukin-6, interleukin-1, tumor ne-
crosis factor alpha, LDL and myeloperoxidase. The biomarkers are applied to anticipate cardio-vascular 
illnesses. Initial diagnoses of these diseases are possible by several techniques; however, they are labo-
rious and need costly apparatus. Current researches designed various bio-sensors for resolving the re-
spective issues. Electrochemical instruments and the proposed bio-sensors are preferred over other 
methods due to its inexpensiveness, mobility, reliability, repeatability. The present review comprehen-
sively dealt with detecting biomarkers of cardiovascular disease through electro-chemical techniques. 
Keywords: Cardiovascular disease, electrochemical biosensors, diagnosis, mortality, C reactive proteins,  
myeloperoxidase. 
1. INTRODUCTION 
One of the abnormalities of the heart and blood ves-
sels, including coronary heart diseases, cerebro- 
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vascular diseases, rheumatic heart diseases, and addi-
tional consequences are Cardio-Vascular Diseases 
(CVD). The World Health Organization (WHO) re-
ported that almost 20 million (31%) mortalities in 2015 
have been associated with cardio-vascular diseases in 
developing and developed countries worldwide [1]. 
Suitable diet, fatness, alcohol abuse, tobacco, anxiety, 
and physical inactivities are known as the common rea-
sons for cardio-vascular disease [2]. It has been pre-
dicted that advancements in general cardio-vascular 
health measures decline mortalities caused by cardio-
vascular diseases to 30% between 2010 and 2020 [3]. 
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Detecting and managing cardio-vascular diseases at the 
initial stages contribute significantly to the clinical di-
agnoses for cases with cardio-vascular diseases or 
those who possibly experience higher risks of cardio-
vascular diseases. It should be noted that this method 
provides on time and survival treatment interventions 
and decreases the healthcare cost. Cardio-vascular dis-
ease is a major risk factor for human health. We face 
the increasing demands due to several causes. Hence, it 
is essential to develop apparatus with suitable mobility, 
accuracy, quickness, sensitivity, reliability, cost-
effectiveness in order to detect this type of disease [4]. 
Today, there is enough knowledge that biomarkers 
identifying CVD bridge when specifying particular 
blood complexes (biomarkers) or changes in their con-
centrations determine different diseases related to car-
dio-vascular diseases [5]. 
Biomarkers could increasingly identify patients with 
higher risks of cardiovascular episodes and assist in 
making decisions on the therapeutic options [6]. Dif-
ferent types of biomarkers are found in the blood serum 
or plasma that include Heart-Type Fatty-Acid-Binding 
Protein (H-FABP), Creatine Kinase MM (CK-MM), 
creatine kinase-MB (CK-MB), myoglobin (MYO), in-
terleukins (IL-1β, IL-6,IL-8), C-reactive protein (CRP), 
tumour necrosis factor alpha (TNF-α), cardiac tropon-
ins (cTnI & cTnT), NT-proBNP, and so forth [7]. 
A variety of methods tested detection of particular 
protein biomarkers for initial diagnoses and efficient 
therapy of stroke, cardio-vascular disease, the respec-
tive risks and inflammations [8]. Conventional methods 
for diagnosing cardio-vascular diseases include Liquid 
Chromatography (LC), enzyme-associated immuno-
sorbent assay (ELISA), immuno-assays, and Surface 
Plasmon Resonance (SPR) that are on the basis of the 
experiments done in central laboratories, which suffer 
from timely procedures [4]. 
Moreover, bio-sensors can be categorized according 
to the principles of selecting analytes. Immuno-sensors 
that interact with antibody and antigen, and with en-
zyme and the target analyte, which are also known as 
enzymatic bio-sensors or nucleic acid-based biosen-
sors. Each conventional (enzyme, antibody & DNA) 
and current components of detection contribute signifi-
cantly to chemical sensors and bio-sensors, which use 
the intended target analyte [9]. Electrochemical im-
muno-sensors are dependent on the measurement of 
current and or voltages for detecting the bind between 
antibodies and antigens [10]. Each sensors have differ-
ent benefits such as cost-effective, sensitive, portable, 
disposable, possible concurrent multi-analysis, reliable, 
little amount of the samples, and rapid responses. 
Therefore, authors paid special attention to the im-
muno-sensors. However, one of the problems can be 
regenerating the attachment sites on antibodies. This 
process is timely and may hurt the binding locations. 
Hence, it is possible that the antibody life declines. 
Sensitive and rapid sequence special data are provided 
by DNA bio-sensors [11]. In spite of the enzyme or 
antibody, synthesis and regeneration of DNA-based 
bio-sensors may be simply performed for a wide range 
of applications. DNA biosensors can be used to exam-
ine molecular diagnostics, pharmaco-genomics, medi-
cal diagnoses, food analyses, environmental monitor-
ing, bio-terrorism and drug screens. The sensor are as-
sociated with various drawbacks such capability of di-
rectly transducing of the signals, preventing the image 
processing, statistical analyses and automating detec-
tion phases [12]. 
A lot of studies dealt with the techniques for devel-
oping bio-sensors, including electro-chemical (conduc-
tometry, potentiometry, amperometry), field effect 
transistor, piezo-electric, capacitor based bio-sensors, 
optic (fluorescence, luminescence, refractive indicator), 
or calorimetric to detect various bio-markers [13]. 
Electrochemical bio-sensors can be regarded a substi-
tute for classic analyses of cardiac bio-markers [14, 
15]. They have several benefits, including user-
friendliness, quickness, accuracy, cost-effectiveness, 
and capability to multi-analyte testings [16]. It is not 
necessary to do costly and laborious experiments for 
designing biosensors techniques. Hence, the costs of 
providing health care services can be reduced. 
Recently, nano-materials have been applied in the 
bio-sensors. Nano-materials possess a lot of advan-
tages, such as conductive features, higher surface or 
volume, and acceptable bio-compatibility that increase 
their function [17]. Nano-materials presented below 
were combined into bio-sensors in order to detect the 
clinically important bio-markers. Carbon based nano-
materials (e.g., carbon nano-tubes (CNT), metal oxides 
(ZnO, CeO2, & Al2O3) metal nano-particles (Ag, Au, 
Pt, Cu), semi-conductors quantum dots (Cd, Se, Ge, 
Te), silicon / indium / gallium, graphene and so on) 
[18, 19]. Gold-based structures (screen-printed elec-
trode (SPE) or nano-materials) have been viewed an 
important component for using in building (bio / nano) 
sensing due to their very good optic, electrical and me-
chanical features [20]. The present review compre-
hensively dealt with detecting biomarkers of car-
diovascular disease through electrochemical tech-
niques. 
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2. CARDIOVASCULAR MARKERS 
Cardiovascular Diseases (CVD) are the major lead-
ing cause of death globally even in developing coun-
tries [21-23]. Hence many scientists are involved in 
searching for tools able to detect the early moments of 
CVD development. Biomarkers have an important role 
in the evaluation of any disease and development of 
drug treatments, especially in Cardiovascular Diseases 
(CVD). The several cardiac-specific biomarkers repre-
sent a biochemical change at heart tissue or blood level 
in cardiovascular diseases condition when the heart is 
damaged or stressed. Recent studies have reported 
some cardiac biomarkers that are associated with 
higher risk of CVD and with CVD risk factors, includ-
ing troponin, Myoglobin, kinase-MB (CK-MB), C-
Reactive Protein (CRP), N-terminal prohormone BNP 
(NT-proBNP), B-type natriuretic peptide (BNP), H-
FABP, Interlukin-6 (IL-6), TNF- α and miRNAs [24-
30]. Some of these biomarkers are useful in prediction 
of Cardiovascular Risk (CVR), while others are can be 
used as the late indicator of heart failure or AMI. 
Moreover, some cardiac biomarkers (predictive bio-
markers) change in their levels adequately mirror im-
provement in the cardiovascular disease process when 
the disease is being treated, thereby reflecting an im-
provement in patient outcome. So, the assessment of 
cardiac marker elevations is helpful to make a reliable 
decision on a suitable treatment. Currently, several 
classifications exist to classify CVD biomarkers. Car-
diac biomarkers can be grouped based on the patho-
physiological processes which they represent, such as 
myocardial necrosis (e.g., cardiac troponin, H FABP, 
myoglobin, and kinase-MB (CK-MB)) inflammation 
(e.g., C-reactive protein, interleukin 6, tumor necrosis 
factor alpha, etc.) myocardial stress (e.g., N-terminal 
prohormone BNP (NT-proBNP), B-type natriuretic 
peptide (BNP) and microRNAs (miRNAs)) (Tables 1 
and 2). In addition to protein biomarkers, recently, ge-
nomic technology has discovered new noncoding RNA 
(miRNAs and LncRNAs) and molecular pathways in-
volved in this disease. MiR-133, miR-21, miR-29 are 
known to play a significant role in regulation of cardiac 
hypertrophy, fibrosis and heart failure [27, 30-33]. A 
long non coding RNA, LIPCAR, is introduced as a 
novel biomarker of cardiac remodeling in patients with 
heart failure [34]. In the last years, several techniques 
for biomarkers detection have been reported. Many of 
them employ antibody-based biosensors as recognition 
elements whereas few techniques are based on the use 
of single stranded DNA or RNA oligonucleotides  
(aptamer) [35-38]. 
3. ELECTROCHEMICAL BIOSENSORS 
Sensor, and in particular, bio-sensors is described as 
an analytical device with a biological sensor in the 
body that is fused with a physico-chemical transducer. 
Biosensors produce a continual digital electrical signal 
corresponding to the quantities of 1 or more analytes 
that are analyzed [9]. In general, they can be fabricated 
via combination of a bio-active component, which has 
interaction in a selective manner with the substance 
that should be analyzed, with a conduction system 
transmitting final signals. As bio-components in bio-
sensors, nucleic acids, anti-bodies, micro-organisms, 
organelles, and enzyme culture may be employed like 
piezoelectric, acoustic, potentiometric, amperometric, 
thermal, and optic sensors. Additionally, as they have a 
greater level of specificity, their benefit is that they can 
measure wider ranges of concentrations directly in the 
coloured and turbid solutions. Yet, biosensors shelf life 
may be declined by the effect of environmental situa-
tions, including pH, ionic strength, and temperature [9]. 
It has been showed that bio-sensors in particularly, 
electrochemical biosensors could be employed for di-
agnosis a variety of biomarkers in various diseases 
[92]. For example, given that carcinoembryonic anti-
gen, miR-34a, miR-24, P16 and a-fetoprotein enable to 
use as electrochemical biosensors in various cancers 
[93].  
Researchers designed bio-sensors to detect CVDs 
bio-marker. Numerous nano-materials were applied to 
fabricate such bio-sensors. Nano-tubes, nano-wires, 
metal nano-particles and polymer based modifications 
have been greatly attended by the researchers because 
of the increased responses of analytes, higher surface 
areas, sensitivities, and selectivities features [94, 95]. It 
is of high importance to increase concentrations of car-
diac bio-markers in serum due to CVD episodes and 
higher rate of mortality. Therefore, it is essential to de-
tect such bio-markers quickly, reliably, and precisely. 
A considerable concentration of CVD bio-markers 
changes between pM - nM; thus, techniques for assay-
ing them should have high sensitivity [17, 96]. Table 3 
reports cut-off values of the bio-markers in the samples 
of serum. 
3.1. Troponin 
Sensitive and reliable methods for cardiac markers 
detection in an early development stage would have a 
fundamental impact on today’s preventive medicine, 
and Cardiac troponin is one of the very early markers 
to increase after AMI onset [135]. Cardiac troponin I 
(cTnI) and T (cTnT) are globular contractile regulatory 
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Table 2. Comparison of predictive biomarkers based on statistical parameters. 
Cardiac Biomarker AUC OR RR  HR 
Troponin I(cTnI) 
AIS: 0.61 [54] CAD: 1.35 [55] 
AMI: 21.7 [56] 





AIS: 1.39 [58] 
ACS: 1.7 [59] 
Troponin T(cTnT) 
ACS: 0.98 [60] 
MI: 0.95 [61] 




AIS: 1.22 [58] 
Myoglobin CD: 0.58 [62] MI: 0.11 [63] - ACS: 1.6 [59] 
Creatine kinase MB subform 
(CK-MB) 
AIS: 0.56 [54] MI: 2.77 [64] MI: 1.3 [65] ACS: 0.9 [59] 
C-reactive protein (CRP) 
CAD: 0.73 [66] CHD: 1.2 [67] 
CHD: 1.58 [68] 
CHD: 1.55 [68] 
AIS: 1.27 [69] 
HF: 2.64 [70] 




CD: 0.83 [62] 
HFpEF patients aged 
≥65 years: 0.761 [72] 
HFpEF patients: 
1.002 [72] 
AIS: 4.88 [73] MACE: 1.84 [74] 
B-type natriuretic peptide(BNP) 
AIS:0.73 [54] 
HFpEF patients aged 
≥65 years: 0.89 [72] 
HFpEF patients 
aged ≥65 years: 
0.891 [72] 
AHF: 0.98 [75] 
- HFpEF patients: 1.5[72] 
MACE: 1.58 [74] 
CD: 1.27 [76] 
Heart fatty acid binding 
protein (H-FABP) 
AMI: 0.81 [77] CVD: 4.21 [78] AMI: 1.48-1.50 
[79] 
HF: 2.1-2.5 [80] 
Interlukin-6 (IL-6) 
AIS: 0.83 [73] 
HFpEF patients aged 
≥65 years: 0.516 [72] 
HFpEF patients 
aged <65 years: 
2.069 [72] 
AIS:4.09 [73] MI: 1.53 
HF: 2.28 [81] 
HF: 1.22 [82] 
TNF-α 
0.67 [72] 
HFpEF patients aged 
≥65 years: 0.64 [72] 
HFpEF patients aged 
≥65 years: 0.67 [72] 
HFpEF patients 
aged ≥65 years: 
0.648 [72] 
HFpEF patients 
aged <65 years: 
1.584 [72] 
- HF: 1.34-2.1 [83] 
MiR-208 AMI: 0.72 [84] AMI: 69 [84] - - 
MiR-1 
AMI: 0.81 [84] 
AMI: 0.77 [85] 
AMI: 12 [84] 
AHF: 1 [75] 
- - 
MiR-499 
CVD: 0.92 [51] 
MI: 0.79 [61] 
AMI: 43 [84] 
HF: 1.7 [61] 
- CAD: 1.913 [86] 
(Table 2) contd…. 
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Cardiac Biomarker AUC OR RR  HR 
MiR-423-5p HF: 0.83 [50] AHF: 0.54 [75] - CS: 1.9 [87] 
MiR-133a 
MI and CAS: 0.918 
[88] 
AMI: 0.932 [85] 
CHD: 0.597 [89] 
CHD: 0.265 [89] - CAD: 2.35 [90] 
MiR-208b  
CVD: 0.94 [51] 
MI: 0.82 [61] 
HF: 1.79 [61] - AMI: 5.08 [91] 
LncRNA-GAS5 CAD: 0.9783 [52] - - - 
lncRNA H19  CAD: 0.631 [53] CAD: 1.126 [53] - - 
lncRNA LIPCAR CAD: 0.722 [53] CAD: 1.306 [53] - - 
Abbreviations: AUC, Area Under ROC Curve; OR, Odds Ratio; RR, Risk Ratio; HR, Hazard Ratio; AIS, Patients with Acute Ischemic Stroke; CAD, Patients 
with Coronary Artery Disease; CHD, Patients with Coronary Heart Disease; ACS, Patients with Acute Coronary Syndrome; MESA, Multi-Ethnic Study of 
Atherosclerosis; CD, Patients with Chagas Diseases; MI, Myocardial Infarction; HFpEF, Heart Failure with Preserved Ejection Fraction; MACE, Major Ad-
verse Cardiovascular Events; CS, Cardiogenic Shock Patients; AHF, Acute Heart Failure; AMI, Patients with Acute Myocardial Infarction; CVD, Patients with 
Cardiovascular Diseases; HF: Heart Failur; CAS, Patients with Coronary Artery Stenosis. 
 
Table 3. The electrochemical biosensors for cardiac biomarkers. 
Sensing Platform  Target  Linear Range  Limit of Detection Refs. 
Carbon nanotube/conductive polymer/antibody cTnI 0.1-10 ng mL-1  0.033 ng mL-1 [97] 
Streptavidin polystyrene/ antibody cTnI 0.1-10 ng mL-1 0.2 ng mL-1 [98] 
Polymer/ antibody/ alkaline phosphatase-antibody cTnI 0.2 ng mL-1 - 10 
µg mL-1 
145 pg mL-1 [99] 
AuNPs/ silver NPs/ antibody  cTnI 0.1 -32 ng mL -1 0.1 ng mL-1 [100] 





2.4 ng mL-1, 
0.03 ng mL-1 
- [102] 
Carboxylated CNT/ antibody cTnT 0.1-10 ng mL-1 0.033 ng mL-1 [97] 
Amin functionalized CNT/ antibody cTnT 0.0025-0.5 ng 
mL-1 
0.0035 ng mL-1 [103] 
Silicon nanowire/ antibody cTnT - 1 fgmL-1 in buffer 
and 30 fgmL-1 in 
human serum 
[104] 













- 1 pgmL-1 [106] 
MB-MWCNT Myoglobin  0.1-3 µM 20 nM [107] 
Antibody/ Au Myoglobin 10-650 ng mL-1 2.5 ng mL-1 [108] 
ZnS nanocrystal/ indium-tin-oxide/ antibody Myoglobin 1 ng mL1- - 1µg 
mL-1 
- [109] 
(Table 3) contd…. 
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Sensing Platform  Target  Linear Range  Limit of Detection Refs. 
Polymers Myoglobin - - [110] 





Bismuth citrate/ antibody/ PbS-quantum dot  CRP 0.2-100 ng mL-1 0.05 ng mL-1 [112] 
ZnO nanotube / antiody CRP 10 -5 - 1 mg L-1 10 -6 mgL-1 [113] 
Antibody/ ECL-antibody CRP 1-24 µg mL -1 - [114] 
Nano porous silica/ antibody CRP 1 pg mL-1 - 1 µg 
mL -1 
1 pgmL-1 [115] 
Single strand DNA/ antibody CRP - - [116] 
MWCNTs/ protein A/ HRP-antibody CRP - 0.5 ng mL-1 [117] 
Carbon nanofibers/ antibody CRP 0.05-0.5 11 ng mL-1 [118] 
polymers CRP 100 fgmL-1 - 
µgmL-1 
1 fgmL-1 [119] 
ZnO nanotube/ antibody CRP 1×10-5- 1.0 mg L-
1 
1× 10-6 mg L-1 [113] 
Polystyrene CRP 1 pg mL-1 - 1 µg 
mL-1 
1 pg mL-1 [120] 
Nanostructural gold/ CNT/ antibody/HRP  BNP 0.02- 100 ng mL-
1 
6 pg mL-1 [121] 
AuNPs/ antibody/ phenyl alanine/ hydroquinone  BNP 0.014-15 ng mL -
1 
4 pg mL -1 [122] 
Nanoporous aluminum oxide/ antibody BNP - 10 fg mL-1 [123] 
Polymer BNP - 50 pg mL-1 [124] 
AChE-labeled antibody BNP 20-40 ng L -1 10 ng L-1 [125] 
Layers of assembly films CK-MB - 0.25 ng mL-1 [126] 
DNA probes  miRNA 100aM-100pM 100aM [127] 
AuNPs/ LNA probe/ HRP miRNA 0.01-700 pM 6fM [128] 
Three-dimensional DNA nanostructure  miRNA  10-107 fM 10 aM [129] 
Probes/ esterase/ quinonimine miRNA  0.002 - 200 nM 2 pM  [130] 
Probe/ TiP-cd+2/ Ru (NH3)6
+3/ AuNPs miRNA  1.0aM-10pM 0.76aM [131] 
Probe/ graphen oxide/ CNT/ RNA-DNA antibody/HRP-
antibody 
miRNA 10fM- 1nM 10fM [132] 
Antibody/ alkaline phosphatase-antibody H-FABP 10-350ngmL-1 - [133] 
Antibody/ alkaline phosphate antibody H-FABP 4-250 ng mL-1 - [134] 
 
proteins that inhibit muscle contraction by blocking the 
interaction of actin and myosin [136]. These two pro-
teins are unique to the heart and are sensitive and spe-
cific biomarkers of vascular events such as an acute 
myocardial infarction, which are released from necrotic 
myocardium into the blood circulation right after AMI. 
The initial elevation of them takes 4-6 h after the onset 
of ischemia and remain elevated for up to a week [137, 
138].  
Acute Myocardial Infarction (AMI) is one of the 
leading causes of death in the world [139]. Thrombus 
formation in the damaged coronary artery due to athe-
rosclerosis, which results in a sudden decrease in the 
amount of blood and oxygen reaching the heart 
(ischemia), it can cause myocardial infarction [140]. 
So, many research groups and companies have a rapid 
and accurate diagnosis and prognosis of this disease. 
An approach for detection of cardiac injury involves 
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measurements of Cardiac troponin in serum or plasma. 
Numerous studies have been carried out that the tro-
ponin C found in type 2 fibers of the skeletal muscle 
and the cardiac muscle; therefore, it is difficult to be 
used as a cardiac specific marker [141]. Unlike tro-
ponin C, cardiac troponin I is highly specific for myo-
cardial tissue, and this type of troponin is not detectable 
in the blood of healthy persons compared with patients 
with myocardial infarction. Therefore, Troponin I is 
particularly useful in diagnosis of risk stratification of 
patients with chest pain and suspected acute coronary 
syndrome due to its superior specificity compared to 
other cardiac biomarkers [142]. In addition, the speci-
ficity and sensitivity of postmortem Troponin T for 
cardiac-related death, in one study, was 91% and 86%, 
respectively [143]. Overall, Troponin T isoforms are 
expressed in injured skeletal muscle and they are not 
detected by the diagnostic assays used in clinical prac-
tice, While Troponin I has been shown to be 100% 
specific for the heart [144].  
Carbon nanostructure is one of the major nanomate-
rial that used in biosensors. Kazemi and colleagues fab-
ricated a label-free electrochemical biosensor using 
porous Grapheme Oxide (GO) for cTnI detection. This 
biosensor could specifically detect target with 0.07 
ng/mL-1 detection limit and linear range of 0.1 to 10 ng 
mL-1 [145]. Liu, et al. designed a label-free electro-
chemical immunosensor for cTnI detection in order to 
myocardial infraction early diagnosis. The Graphene 
Oxide (GO) and gold nanoparticles (AuNPs) were im-
mobilized on Glassy Carbon (GC) electrode which 
provided a big surface area platform to load cTnI anti-
body and also, accelerated electron transfer. Finally, 
GO functionalized with ferrocene molecules, as the 
signal reporter, covered detection antibody. The sche-
matic figure is illustrated in Fig. (1). The presented 
biosensor could detect 0.05 ng mL-1 cTnI concentration 
[146]. Jo et al. developed an aptasensor using fer-
rocene-modified silica nanoparticles (Fc-SiNPs) to de-
termine TnI. In the presence of target protein, the volt-
ammetry curve of Fc-SiNPs fell down remarkably, be-
cause the TnI bonded to aptamers blocked the electrode 
surface, so, the electron transfer was inhibited. In this 
scenario, the TnI could be detected in linear range of 1-
10,000 pM and limit of detection was found to be 1.0 
pM [147]. Anti-cTnI was immobilized on vertically 
aligned Carbon Nanofiber (CNF) for electrochemical 
detection of cTnI (Fig. 2). This immunosensor demon-
strated a low detection limit of about 0.2ng/ml, which 
is 25 times more sensitive than conventional methods 
[148]. Streptavidin coated AuNPs (SA-AuNPs) immo-
bilized on electrode. Coated AuNPs with luminol, a 
chemilluminescence (ECL) agent, conjugated with bio-
tin-anti-cTnI (biotin-anti-cTnI-luminol-AuNPs) bonded 
to SA-AuNPs. The fabricated biosensor is shown in 
Fig. (3). Changes in ECL signals during anti-cTnI and 
 
Fig. (1). Schematic of AuNPs and GO nanocomposite biosensor for detection cTnI. 
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antigen reactions was used for cTnI detection in plasma 
samples. This nanobiosensor exhibited a detection 
range from 1000ng mL-1 to lower than 0.1 ng mL-1 
[149].  
3.2. C-reactive Protein 
C-reactive protein is a long plasma half-life protein 
(The average plasma half-life of CRP is about 19 
hours), and it is a sensitive systemic biomarker for in-
flammatory events and tissue damage [150]. CRP is 
25KDa and it can adapt a circular form constituted by 
five equal subunits that Each subunit binds to two cal-
cium ions by intermolecular noncovalent salt bridges 
[36, 151]. It is Produced and secreted mainly by liver in 
response to interleukin-6 (IL-6) and either IL-1 or tu-
mor necrosis factor-alpha. High levels of this protein 
are related with a large clinical state of diseases such 
as: inflammation both acute and chronic, cardiovascu-
lar diseases and bacterial infections (1000-fold over 
baseline) [152-155]. Research and developments in this 
area have proved that CRP can predict mortality and 
cardiovascular events, such as myocardial infarction 
(MI) and stroke [28, 156, 157]. More recently, CRP has 
been used as a general marker for Inflammation con-
tributes to all phases of atherosclerosis, from fatty 
streak initiation to Cardiovascular Disease (CVD) 
events [158, 159]. Also, plasma CRP concentration 
increases following MI that was first reported in 1982 
[160]. Subsequent large studies have shown that post-
infarct CRP concentrations are significantly associated 
with increased incidence of cardiac complications such 
as cardiac death and heart failure [24]. To data, Meas-
urement of C-reactive protein may be useful for risk 
assessment in patients with coronary heart disease. 
Clinical reference ranges for CRP assay are described 
as ≤1 μg·mL-1 for low risk, 1-3 μg·mL-1 for medium 
risk and ≥3 μg·mL-1 for high risk [161]. In healthy 
normal subjects, CRP is a trace plasma protein (<5 
mg/L) and its concentration tends to increase slightly 
with age [162].  
Gupta and colleagues provided an electrochemical 
CRP biosensor. The immobilized anti-CRP on carbon 
nanofiber was used as biosensing platform. The sensor 
had detection limit about 11 ng mL-1 with a desirable 
specificity [163]. In another research a highly sensitive 
biosensor for CRP in serum was reported. The anti-
CRP immobilized on standard polycrystalline gold 
electrodes. The limit of detection was found to be 176 
pM and the linearity with log CRP concentration was 
in the range of 0.5-50 nM. This biosensor showed very 
ideal selectivity and regeneration after assay without 
loss of sensitivity [164]. The interaction between anti-
CRP immobilized on electrode and CRP was investi-
gated using electrochemical techniques. This methods 
could effectively probe CRP concentration in a wide 
range, from 1.15 × 10-5 to 1.15 mg L-1 [165]. Wang  
et al. provided an electrochemical aptasensor for CRP 
detection. Firstly, silica microspheres functionalized 
with AuNPs, provided large surface area for immobi-
lizing anti-CRP and Zn2+ as signal molecules (silica- 
 
Fig. (2). Carbon nanofiber based electrochemical biosensors for cTnI. 
 
 
Fig. (3). immunosensor label-free for detection troponin I. 
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AuNPs- anti-CRP- Zn2+). CRP-aptamer were immobi-
lized on AuNPs modified electrode (AuNPs-aptamer 
electrode). The fabricated biosensor scheme is illus-
trated in Fig. (4). In the presence of CRP, a sandwich 
structure was formed and Zn 2+ reductive peak was re-
corded clearly. This apatasensor showed linearity in the 
range from 0.005 ng mL-1 to 125 ng mL-1 and detection 
limit as low as 0.0017 ng mL-1 of CRP concentration 
[166]. Liu and colleagues introduced Metal-Organic 
Frameworks (MOFs) as signal probes. They presented 
a electrochemical immunoassay using Au-MOFs for C-
reactive detection [167]. MOFs are component consist 
of metal ions or clusters bonded by organic bridging 
ligands to form one, two, or three dimensional struc-
tures [168, 169].  
3.3. Myoglobin 
Myoglobin (Myo) is an intracellular O2 binding 
hemoprotein in heart and skeletal muscle. Cardiac my-
oglobin is one of the very early markers to increase 
after AMI onset and it was introduced as the first 
nonenzymatic protein used for AMI diagnosis [170]. 
Myoglobin has some value characterize including the 
small size of the molecule (17.8 kDa), facilitating quick 
release into blood (as early as 1-3 h upon AMI onset), 
and reaching the maximum between 6 and 12 h after 
the first symptoms of muscle damage [40]. So, its high 
sensitivity and high predictive value makes myoglobin 
a valuable early screening test for AMI [171]. Because 
of myoglobin rise and fall more rapidly, this marker 
continues to be used in certain clinical scenarios such 
as reinfarction, infarct extension and early onset chest 
pain. Isakov et al. demonstrated that Serum myoglobin 
levels were elevated in 178 patients with acute myo-
cardial infarction compared to the normal control cases. 
Their data showed that serum myoglobin is a reliable 
measure of myocardial necrosis and appears to be re-
lated to infarct size [172]. Thielmann et al. showed that 
 
Fig. (4). Aptasensor based on electrochemical detection of C-reactive. 
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the Myoglobin levels have a higher difference at 12 h 
after aortic unclamping as compared to troponin I at the 
same time point. So, this protein is introduced as an 
earlier marker for myocardial ischemia than troponin I 
[29]. whereas it has cross-activity with skeletal muscle 
injury[173] and somewhat lower sensitivity and speci-
ficity, this marker of myocardial ischemia might be 
useful in addition to troponin I as an early warning sign 
of myocardial diseases. 
For direct electrochemically detection, myoglobin 
was immobilized on AuNPs and Multi Wall Carbon 
Nanotubes (MWCNTs) [174]. Cobalt nanoparticles 
(CoNPs) on carbon ionic liquid electrode was used as a 
myoglobin electrochemical sensing platform [175]. 
Ruan, et al. applied a sensing approach based on gra-
phene, ionic liquid and chitosan composite for the my-
oglobin immobilization. The high conductivity of ionic 
liquid and graphene, large surface to volume ration of 
graphene, and chitosan biocompatibility increased my-
oglobin absorption and direct electron transfer between 
protein and electrode [176].  
 Pur et al. fabricated an ECL based for early detec-
tion of myoglobin. Aptamer was used for specifically 
detection of globin in serum and urine samples. The 
linearity of biosensor was in the range of 0.05 to 25 nM 
myoglobin concentration, with detection limit of 12pM 
[177]. Black phosphorus, also known as phosphorene, 
is a two-dimensional nanostructure which is very much 
like graphite in terms of similarity in black and flaky 
form, electrical conductivity and having sheets of 
linked atoms [178]. In this structure each atom bonds 
covalently with three neighboring atoms to give a hon-
eycomb structure [147]. An electrochemical based ap-
proach using aptamer-functionalized black phosphorus 
was reported to detect myoglobin. Black phosphorus 
with aptamers provided a biosensing platform with im-
proved selectivity and sensitivity compared to conven-
tional detection methods. The presented sensor has de-
tection limit of 0.524 pg mL-1 with a dynamic response 
range from 1pg mL-1 to 16µg mL-1 for serum myoglo-
bin [179]. Moreira et al. used polymers for electro-
chemically myoglobin detection with 2.25 µg mL-1 
[180]. 
3.4. Creatine Kinase-MB 
Creatine kinase (CK) is a key enzyme of cellular 
energetics with a number of isoenzymes consists of 
CK-MM, CK-MB, CK-BB and mitochondrial-CK. 
Each subunit of the dimeric CK is expressed in a tis-
sue-specific manner that is regulated by a distinct gene 
[181]. CK-MB is found predominately in the human 
myocardium; with concentration ranges from 5 to 30% 
of the total CK activity of the heart [182]. Voss et al. 
demonstrated, in 1995, that the tissue distribution of 
CK-MB in normal and diseased human heart tissue 
showed a 30% increase in CK MB in diseased left ven-
tricles and a 35% increase in diseased right ventricles 
compared to normal myocardium [183]. A recent report 
which is studied in the acute LAD occlusion showed that 
myocardial CK-MB globally increased 3-fold at 5 h after 
occlusion [184]. This study confirmed Ingwall’s earlier 
report which represented, in normal hearts obtained from 
young, that the CK-MB composition was found to be < 
2% [185]. Moreover, the CK-MB content of skeletal 
muscle in patients with Duchenne’s muscular dystrophy 
was found to be part of a dynamic process influenced by 
numerous cellular events [186]. In conclusion, CK-MB 
is not 100% specific for the heart so; increased serum 
CK-MB concentrations must be evaluated cautiously 
and taken in context with clinical findings. 
CK-MB plays a phosphor-transferase role in creatin, 
so, the phosphate presence is necessary [187, 188]. 
Phosphorylated creatine (Pcrea), an electroactive com-
pound, was immobilized on Au electrode and electro-
chemical spectroscopy methods were applied to follow 
the chemical modifications in the electrode. CK-MB in 
solution consumed the Pcrea and caused a significant 
change in electrical response (Fig. 5). The limit of de-
tection was 0.11 µg mL-1 and performed specific in 
presence of bovine serum albumin (BSA), TnI and my-
oglobin [189].  
Lee et al. fabricated biosensor base on single site-
specific Polyaniline (PANI) nanowire with monoclonal 
antibodies which could detect cardiac biomarker. In 
this scenario, cTnI, BNP, myoglobin and CK-MB 
could be simultaneously detect in 250 fg mL-1, 50 fg 
mL-1, 100 pg mL-1 and 50 fg mL-1 concentrations, re-
spectively [105]. Prakash and colleagues reported an-
other multiplexed electrochemical immunosensor that 
simultaneously detected cardiac markers including 
cTnI, myoglobin and CK-MB. MWCNTs embedded 
epoxy-based negative photoresist (SU-8) were func-
tionalized with specific antibody. Using these hybrids 
caused overcoming their respective shortcomings, 
MWCNTs minimal functional groups and low conduc-
tivity for SU-8. The linear range for cTnI, myoglobin 
and CK-MB were found to be 0.1-10 ng mL-1, 1-50 ng 
mL-1 and 10-10,000 ng mL-1, respectively [190].  
3.5. B-type Natriuretic Peptide  
B-type Natriuretic Peptide (BNP) is a cardiac neu-
rohormone initially identified in the brain. Multiple 
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studies have identified that this protein has secreted 
from the heart, particularly the ventricles as a response 
to heart failure with the progression of clinical symp-
toms, and then its levels go down when heart failure is 
stable. [191, 192]. The pre-prohormone BNP (proBNP) 
cleaved to biologically active 32-aminoacid BNP and 
non-biologically active 76-aminoacid N-terminal pro-
BNP (NT-proBNP) [193]. Recent studies have shown 
that the concentration of BNP and NTproBNP are in-
creased in a variety of cardiovascular conditions, per-
mitting their use in diagnosis [194]. Clerico and col-
leagues revealed that serum BNP was potentially useful 
tools as a novel biomarker for discriminating between 
normal subjects and patients with different degrees of 
heart failure. Data showed that protein Levels of B-
type natriuretic peptide were significantly elevated in 
patients with left ventricular dysfunction in their serum 
samples when compared with normal controls [192]. 
According to results of the clinical studies performed 
by Maisel, rapid measurement of B-type natriuretic 
peptide is useful in establishing or excluding the diag-
nosis of congestive heart failure in patients with acute 
dyspnea [26]. 
Several other novel biomarkers are also being ex-
plored as potential heart failure biomarkers, such as 
NT-proBNP [25], H-FABP [195], Interlukin-6 (IL-6) 
[196], TNF-α [197], Myeloperoxidase (MPO) [198]; 
however, some of these are yet to be fully investigated 
in larger, non-selected samples for their association 
with incident heart failure. 
Simple, acute and reliable evaluation of blood BNP 
level is of importance for diagnose and distinguish 
heart failure patients from other dyspnea ones [199]. 
Electrochemical techniques combined with signal am-
plifiers seem to be appropriate for gain this purpose 
[200].  
Matsuura et al. presented an electrochemical en-
zyme assay to determine BNP. Anti-BNP functional-
ized with acetylcholinesterase (AChE) undergone with 
BNP as target; so the immunological reaction occurred. 
Further, BNP-AuNPs were added into solution and 
bonded to unreacted AChE-anti-BNP; in this way they 
removed from solution [201]. AChE is a very highly 
active cholinesterase which catalyzes breakdown of 
acetylcholine and some other choline esters [202, 203]. 
Eventually, the AChE activity evaluated based on thiol-
production chemisorption on an Ag electrode. Finally, 
AChE reaction caused thiocholine chemisorption 
which resulted in improved sensitivity for BNP. In this 
platform 20-200 pg mL-1 of BNP concentration could 
be determined [201]. Recently, Hartati, et al. developed 
immunosensor with the streptoavidin/biotin based on 
electrochemical techniques. Biotinylated anti-BNP as 
capture antibody decorated on steptoavidin-modified 
electrode. In the presence of BNP, the immunological 
reaction occurred between BNP protein and capture 
antibody. An anti-BNP conjugated with horseradish 
peroxidase (HRP), as the secondary antibody, and 
3,3,5,5'-tetramethybezidine dihydrochloride (TMB) 
were used to measure the peak current. The schematic 
procedure of this sensing platform is shown in Fig. (6). 
The detection limit of 3.3 ng mL-1 and a linear detec-
tion range from 0.001 to 100 ng mL-1 were recorded for 
BNP concentration [204]. 
Recently, Shanmugam et al. reported multianalyte 
device for simultaneous detection of cTNI, troponin 
and BNP. Due to high isoelectric point of pH9.5, ZnO 
NPs facilitated electron transfer. The antibodies spe-
 
Fig. (5). Simple electrochemical biosensor for detection creatine kinase using PCrea. 
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cific for each biomarker were immobilized on ZnO 
NPs. In this scenario, dynamic range from 1 pg mL to 
100 ng mL-1 and limit of detection at 1pg mL-1 were 
obtained for three biomarkers in human serum samples 
[205].  
3.6. Noncoding RNA 
Advanced genomics technologies have revealed 
noncoding regulatory RNAs representing supernatural 
diversity in size, structure, and molecular function 
[206]. The levels of individual ncRNA and specific 
ncRNA signatures are linked to the diagnosis and 
prognosis for diseases. Recently, increasing evidence 
suggests that noncoding RNAs have a putative role in 
the pathophysiology of cardiovascular disease [207, 
208]. Noncoding RNAs can be divided into small 
(<200 nt) noncoding RNAs and long noncoding RNAs 
(lncRNAs) [206]. Among the small noncoding RNAs, 
micro RNAs have been studied extensively in cardio-
vascular diseases. Several studies showed the associa-
tions of microRNA to cardiac hypertrophy and cardiac 
fibrosis, and make them an attractive biomarker to 
guide future heart failure therapy [209, 210]. They can 
act as a player in regulation of cardiac fibrosis e.g. mi-
croRNA-29 [30] microRNA-21 [32], hypertrophy (e.g. 
microRNA-133) [31], and heart failure [33]. One study 
has even found that several cardiac microRNAs are 
detectable in blood early after myocardial infarction. 
Wang et al. showed that elevated cardiac-specific miR-
208a in human plasma may be a novel biomarker for 
early detection of myocardial injury. Their result 
showed that miR-208a was undetectable in non-AMI 
patients, but it was easily detected in 90.9% AMI pa-
tients and in 100% AMI patients within 4 h of the onset 
of symptoms [48].  
In addition, long noncoding RNAs [211] have since 
also been evaluated by several investigators in relation 
to the pathological process of a variety of cardiovascu-
lar diseases, including AMI [212], Heart Failure (HF) 
[34], and congenital heart disease [181]. Kumarswamy 
et al. provide evidence that late circulating levels of the 
lncRNA named LIPCAR, are associated with adverse 
outcomes after myocardial infarction and in chronic 
heart failure [34]. However, at the present time, studies 
about circulating noncoding RNA as a clinical bio-
marker of AMI is still in its infancy, and measurement 
of both microRNAs and long noncoding RNAs to es-
tablished heart failure biomarkers, and their stability 
and reliability in diagnosing AMI still requires further 
exploration. 
Electrochemical biosensors have the potentials to 
meet a suitable devise for miRNA detection because of 
their simplicity, low cost and sensitivity [213]. In this 
section we propose, specific and promising examples 
of electrochemical platform for miRNA detection.  
Wu et al. proposed a miRNA biosensor based on 
hybridization chain reaction and catalyzed hairpin as-
sembly. They used four label-free hairpin probes 
named H1 to H4 decorated on AuNPs-graphene 
nanohybrid film. Firstly, the H1, as the capture probe, 
was opened in the presence of target miRNA. 
Hybridization H1 with H2 resulted in getting free the 
 
Fig. (6). Immunosensor detection of BNP cardiac biomarker using HRP enzyme. 
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H1 with H2 resulted in getting free the target miRNA. 
The released miRNA rehydride with reaming H1 
probe. After target recycling process, the H1-H2 hy-
brids was exposed with H2 stem which served as HCR 
initiator. Finally, Methylene Blue (MB), is an electro-
chemical indicator, intercalated into double strand 
DNAs to amplify electrochemical signals. The Fig. (7) 
illustrated this sensing platform. The linearity ranged 
from 10fM to 1nM [214]. An electrochemical genosen-
sor based on inosin-modified capture probe was pre-
sented for miRNA detection. Due to probe-target 
miRNA hybridization the inosin was oxide to guanine 
which caused an electrical signal [215]. In a miRNA 
electrochemical biosensor, the morpholino capture 
probe immobilized on Indium Tin Oxide (ITO)-
functionalize electrode [216]. Morpholino oligomers 
are DNA base attached to methylenemorphone rings 
via phosphodiester bonds. It is worth notice that they 
have neutral charge and are resistance to enzyme deg-
radation [217, 218]. Hybridization of target miRNA 
and probe converted the neutral surface to anionic, due 
to hybridized miRNA strand. Then, HRP enzyme em-
bedded in polymers added to sensing platform. The 
electrochemical signals were produced in the presence 
of H2O2. The linearity miRNA concentration ranged 
from 5.0 fM to 2.0 fM and the detection limit was 
found to be 2.0 fM [216]. 
CONCLUSION  
Valuable insights can be available for the clinicians 
through cardiac bio-markers, which assist them diag-
nosing, prognosing, and deciding on the patients' thera-
peutic options in order to provide immediate remedies 
while seeing myocardial infarction symptoms. There 
are a growing papers studying the cardiac bio-markers 
detection. Numerous techniques have been proposed 
for analyzing and detecting via optical, chemi-
luminescence, radio-immunoassay, and enzyme associ-
ated immuno-sorbent assay techniques. However, they 
suffer from a lot of challenges, including long-term 
usage, costly devices, and pre-treatment procedures. In 
spite of the above techniques, electro-chemical proce-
dures enjoy interesting characteristics, such as rapid-
ness, mobility, inexpensiveness, reliability, accuracy, 
and so forth. The present review aims at summarizing 
current researches conducted on detecting CVD bio-
markers through electro-chemical techniques. It was 
found that SWV, EIS and DPV are greatly attracted 
due to detecting cardiac bio-markers. In general, EIS 
technique was applied to characterize the morphologies 
of sensors in order to demonstrate various substances 
over the sensor surface. Optimization of DPV and 
SWV techniques have been done for sensitively detect-
ing of cardio-vascular bio-markers. 
 
Fig. (7). Electrochemical biosensor based on Go functionalized AuNPs for dual amplification miRNA detection. 
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Moreover, the study presents nano-particles with the 
widespread application in making bio-marker bio-
sensors. With regard to the review of the publications, 
gold- and carbon-based nano-particles are frequently 
used to detect cardiac bio-markers. Nano-materials are 
largely attracted due to integrating into bio-sensor ap-
paratus, because detecting sensitiveness and values of 
detection limit may be improved by such nanomateri-
als. Thus, simple synthesizing and integrating into each 
sensor are their advantages.  
Future researches should detect cardio-vascular bio-
markers at the clinic because of the convenient pro-
curement process to measure and rapid use through 
blood or additional biological specimens obtained from 
the participants. Biomarkers can help management de-
cisions, fast and precise diagnoses, and risks stratifica-
tions. They contribute invaluably to the provision of 
efficient healthcare and minimize healthcare charges. 
They also may predict numerous cardio-vascular dis-
eases. Currently, authors paid increasingly attention to 
the application of the lab-on a chip bio-sensors, which 
are called mobile sensing, on the basis of smart phone 
and micro-fluidic instruments. Such instruments enjoy 
influential imaging and computation abilities for gain-
ing rapid data achievement and reporting. These char-
acteristics are of high importance to the personnel and 
participants. Lab-on a chip sensor will be employed in 
the cardiac illnesses and diagnoses of disease in the 
future. 
LIST OF ABBREVIATIONS 
AChE = Acetylcholinesterase 
AMI = Acute Myocardial Infarction 
AuNPs = Gold Nanoparticles 
BNP = B-Type Natriuretic Peptide 
BSA = Bovine Serum Albumin 
CK = Creatine Kinase 
CK-MB = Creatine Kinase-MB 
CK-MM = Creatine Kinase MM 
CNF = Carbon Nanofiber 
CNT = Carbon Nano Tubes 
CoNP = Cobalt Nanoparticles 
CRP = C-Reactive Protein 
cTn = Cardiac Troponin 
cTnI = Cardiac Troponin I 
cTnT = Cardiac Troponin T 
CVD = Cardiovascular Diseases 
CVR = Cardiovascular Risk 
DNA = Deoxyribonucleic Acid 
DPV = Differential Pulse Voltammetry 
ECL = Enhanced Chemilluminescence 
EIS = Electrochemical Impedance Spectros-
copy 
ELISA = Enzyme-Associated Immuno-Sorbent 
Assay 
Fc-SiNPs = Ferrocene-Modified Silica Nanoparti-
cles 
GC = Glassy Carbon 
GO = Graphene Oxide 
H1 = Hairpin Probe 1 
H2 = Hairpin Probe 2 
H3 = Hairpin Probe 3 
H4 = Hairpin Probe 4 
HFABP = Heart Type Fatty Acid Binding Protein 
HRP = Horseradish Peroxidase 
IL = interleukin 
ITO = Indium Tin Oxide 
LAD = Left Anterior Descending Coronary 
Artery 
LC = Liquid Chromatography 
LDL = Low-Density Lipoprotein 
LIPCAR = Long Non-Coding Cardiac Associated 
RNA 
LncRNA = Long Non-Coding RNA 
MB = Methylene Blue 
MI = Myocardial Infarction 
MiR = MicroRNA 
miRNA = microRNA 
MOF = Metal-Organic Framework 
MPO = Myeloperoxidase 
MWCNT = Multi Wall Carbon Nanotube 
MYO = Myoglobin 
ncRNA = Noncoding RNA 
NT-proBNP = N-Terminal Pro b-Type Natriuretic 
Peptide 
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PANI = Polyaniline 
Pcrea = Phosphorylated Creatine 
Pro-BNP = Pre-Prohormone b-Type Natriuretic 
Peptide 
RNA = Ribonucleic Acid 
SA-AuNPs = Streptavidin Coated AuNPs 
SPE = Screen Printed Electrode 
SPR = Surface Plasmon Resonance 
SWV = Square Wave Voltammetry 
TMB = Tetramethylbenzidine Dihydrochloride 
TNF-α = Tumor Necrosis Factor Alpha 
WHO = World Health Organization 
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